Title of article
Skeletal safety of tiludronate
Author/Authors
R. M. Neer، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 1995
Pages
3
From page
501
To page
503
Abstract
The medical uses of bisphosphonates derive from their exceptional ability to inhibit bone resorption. However, bone resorption is essential for the healing of fractures, the repair of microscopic fatigue cracks in bone, and the internal reorientation of trabecular and cortical bone in response to altered mechanical strains. In theory, overdose with bisphosphonates might interfere with the repair of fractures or weaken bone strength (by forcing bones to accumulate and propagate fatigue cracks or by abolishing the skeletonʹs adaptive powers). Regulatory agencies (particularly in the USA) have, therefore, set comprehensive and stringent safety criteria before the marketing of bisphosphonates can be approved. Some bisphosphonates can also inhibit bone mineralization, alter hepatic function, or cause gastritis/ esophagitis. The safety profile of tiludronate will be described from this perspective, emphasizing the results of prolonged treatment in animals, and studies in humans.
Keywords
Tiludronate , Resorption , fractures , Pagetיs disease , Cortical , mineralization , Trabecular
Journal title
Bone
Serial Year
1995
Journal title
Bone
Record number
489952
Link To Document